Participants in a hydroxychloroquine study enrolled on a website and received medicines overnight by FedEx. By Kai KupferschmidtScience’s COVID-19 reporting is supported by the Pulitzer Center.Yesterday, The New England Journal of Medicine (NEJM) published the highly anticipated results of a clinical trial of hydroxychloroquine to prevent COVID-19.
The study, led by David Boulware of the University of Minnesota, Twin Cities, enrolled 821 healthy adults who were at risk of the disease: They had been in close proximity to a COVID-19 patient for more than 10 minutes, either at home or at work, without wearing full protection.The trial showed no benefit from hydroxychloroquine; 12% of the people who took the drug went on to develop symptoms of